According to Vujicic et al. (2016), the possible interaction of EtOAc with TLR4 (Toll-like receptor 4) function would make this extract a possible candidate for the treatment of immunoinflammatory and autoimmune diseases such as systemic lupus erythematosus, uveitis, inflammatory bowel disease, arthritis, and diabetic nephropathy, which seem to benefit from TLR4 blockade in the preclinical setting [498]. The gene discussed is TLR4; the disease is systemic lupus erythematosus.